

administering to said patient 1 $\mu\text{g/kg/hr}$ to about 50 $\mu\text{g/kg/hr}$ of human activated protein C.

Sub B1 12. The method according to Claim 1, wherein the patient is administered 5 $\mu\text{g/kg/hr}$ to about 30 $\mu\text{g/kg/hr}$ of human activated protein C.

A2
concl 13. The method of Claim 12, wherein the human activated protein C is administered by continuous infusion for about 1 to about 240 hours.

14. A method of treating heparin-induced thrombocytopenia in a patient, which comprises administering human activated protein C in an amount to achieve an activated protein C level in said patient from 2 ng/ml to about 300 ng/ml.

15. The method of Claim 14 wherein the activated protein C is administered in a bolus injection.

16. The method of Claim 15 wherein the activated protein C is administered by continuous infusion for about 1 to about 240 hours.

17. The method of Claim 14 wherein the activated protein C is administered first as a bolus then as a continuous infusion. *and*

Remarks

Applicants request consideration of the claims as amended and allowance of this patent application.

Respectfully submitted,

Brian P. Barrett

Brian P. Barrett
Attorney for Applicants
Registration No. 39,597
Phone: 317-276-7243

Eli Lilly and Company
Patent Division/BPB
Lilly Corporate Center
Indianapolis, Indiana 46285

May 10, 2001